Ion Mobility Mass Spectrometry Training Network

离子迁移率-高分辨质谱（IM-HRMS）是研究和工业中的下一代分析平台。释放其在生物治疗、环境和食品安全等各种应用中的全部潜力，不仅需要推动仪器、基本理解和应用的前沿，而且协调也至关重要。为了实现这一目标，需要仔细检查和克服目前在跨仪器类型、实验室和研究领域的数据收集、分析和报告方面的缺陷。MobiliTraIN博士网络将形成10名博士候选人（DC），他们将带来对IM-HRMS的新的基本理解，提供标准化的参考材料和指导方针，为IM-HRMS在生物制药开发、生物组学研究和污染物非靶筛选中的应用开发最先进的方法，并为IM-HRMS在工业中的应用奠定基础。通过跨学科的研究计划，包括开放科学方法和技术、商业和可转移技能的培训，MobiliTraINDC将成为离子迁移领域的领先专家，拥有独特的技能，成功地推进他们的职业生涯，同时支持欧洲的创新能力。在现有合作和卓越研究的基础上，涵盖IM-HRMS开发和应用的整个创新链，MobiliTraIN联合了来自8个国家的8家学术机构、3家领先的仪器公司、1家监管机构、1家制药行业领导者和5家中小企业。凭借互补的专业知识，技术诀窍和指导经验，我们的联盟非常适合揭示IM-HRMS作为更安全治疗的关键技术的潜力，更好地了解复杂疾病的进展，并改善食品，水和公共卫生安全的监测。

Ion mobility-high resolution mass spectrometry (IM-HRMS) is the next-generation analytical platform in research andindustry. Unlocking its full potential across applications as varied as biotherapeutics, environment and food safety requiresnot only pushing back the frontiers of instrumentation, fundamental understanding and applications - but harmonisation isessential. To achieve this, current shortcomings in data collection, analysis and reporting across instrument types,laboratories and research areas need to be scrutinised and overcome.The MobiliTraIN Doctoral Network will form 10 Doctoral Candidates (DCs) who will bring a new fundamental understandingof IM- HRMS, provide reference materials and guidelines for standardisation, develop state-of-the-art methods for theapplication of IM- HRMS in biopharmaceutical development, biological 'omics studies, and nontarget screening ofcontaminants, and lay the foundations for IM-HRMS adoption in industry. Through an interdisciplinary researchprogramme, including an open science approach and training in technical, business and transferable skills, the MobiliTraINDCs will become leading experts in ion mobility with a unique skill set to successfully advance their careers whilesupporting Europe's innovation capacity.Building on existing collaborations and research excellence covering the entire innovation chain of IM-HRMS developmentand application, MobiliTraIN unites 8 academic institutions, 3 leading instrumentation companies, 1 regulatory agency, 1pharma industry leader and 5 SMEs from 8 countries. With complementary expertise, know-how and mentoringexperience, our consortium is ideally suited to unveil the potential of IM-HRMS as a key technology for safer therapeutics,better understanding of complex disease progression and improved monitoring of food, water and public health safety.